

GLAXOSMITHKLINE PLC  
Form 6-K  
March 09, 2012

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending March 2012

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--



Notification of Transactions of Directors, Persons Discharging  
Managerial Responsibility or Connected Persons

This notification sets out information relating to conditional share awards granted in 2009 under the GlaxoSmithKline 2009 Performance Share Plan (the Performance Share Plan), the vesting in part (49%) of which was approved by the Remuneration Committee on 17 February 2012, following a three-year performance period (the Awards).

The ex-dividend date for the fourth quarter 2011 and supplemental dividends (the Dividends) was 15 February 2012. In accordance with the rules of the Performance Share Plan, the Dividends on the vested Awards were reinvested in further shares at prices of £14.21 per Ordinary Share and \$44.48 per American Depositary Share (ADS), being the prices on 15 February 2012. This resulted in the vesting and lapsing of the following shares on 8 March 2012, in proportion to the vesting of Awards approved by the Remuneration Committee on 17 February 2012.

|                   | Percentage of<br>total Awards<br>which vested | Vested<br>Ordinary<br>Shares | Lapsed<br>Ordinary<br>Shares |
|-------------------|---|------------------------------|------------------------------|
| Sir Andrew Witty* | 49%   | 4780                         | 2048                         |
| Mr S M Bicknell   | 49%   | 216                          | 92                           |
| Mr J M Clarke     | 49%   | 782                          | 334                          |
| Mr M Dunoyer      | 49%   | 402                          | 170                          |
| Mr E Gray         | 49%   | 508                          | 217                          |
| Mr A Hussain      | 49%   | 782                          | 334                          |
| Mr D S Redfern    | 49%   | 295                          | 125                          |
| Mr J R Stephenne  | 49%   | 508                          | 217                          |
| Ms C Thomas       | 49%   | 402                          | 170                          |

\* denotes an Executive Director

|               | Percentage of total<br>Awards which<br>vested | Vested<br>ADSs | Lapsed<br>ADSs |
|---------------|---|----------------|----------------|
| Dr M Slaoui*  | 49%   | 709            | 302            |
| Ms D Connelly | 49%   | 791            | 338            |
| Mr W C Louv   | 49%   | 257            | 109            |
| Dr D Pulman   | 49%   | 396            | 168            |
| Mr D Troy     | 49%   | 593            | 253            |

\* denotes an Executive Director

The Company, Directors and Persons Discharging Managerial Responsibility were advised of these transactions on 8 March 2012.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rules 3.1.4R(1)(a).

V A Whyte  
Company Secretary  
9 March 2012



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: 09 March 2012

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc